Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MARY MARGARET MOORE

Allopathic & Osteopathic Physicians Dermatology

NPI
1134314263
CMS profile
232336
Location
MISSOURI CITY, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$6,884.73

340 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $5,000.73 338
Consulting Fee $1,785.00 1
Education $99.00 1

By paying entity

PY2025 · entire year · sorted by reported total

Page 3 of 7; records 101–150 of 340 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MARY MARGARET MOORE

NPI 1134314263 · CMS profile ID 232336

Allopathic & Osteopathic Physicians / Dermatology

MISSOURI CITY, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 7; records 101–150 of 340 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1134314263?year=2025&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MARY MARGARET MOORE, NPI 1134314263, CMS profile ID 232336. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 7; records 101–150 of 340 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1134314263?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). MARY MARGARET MOORE, NPI 1134314263, CMS profile ID 232336. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 7; records 101–150 of 340 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1134314263?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
MARY MARGARET MOORE, NPI 1134314263, CMS profile ID 232336, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 7; records 101–150 of 340 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1134314263?year=2025&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

340 matching records · $6,884.73 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 340 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 340.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Regeneron Healthcare Solutions, Inc. $31.4609/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1212993661 CMS
Amgen Inc. $6.5409/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227073022 CMS
Galderma Laboratories, L.P. $22.9909/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234680580 CMS
LEO Pharma Inc. $2.7409/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1252024039 CMS
Arcutis Biotherapeutics, Inc. $9.7409/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1252359365 CMS
MAYNE PHARMA COMMERCIAL LLC $6.7009/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1254275958 CMS
ABBVIE INC. $6.1309/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1203126401 CMS
Incyte Corporation $19.0409/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1226163582 CMS
E.R. Squibb & Sons, L.L.C. $18.2309/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184545073 CMS
ABBVIE INC. $8.1009/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1203126398 CMS
Janssen Biotech, Inc. $35.1309/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175104436 CMS
Arcutis Biotherapeutics, Inc. $12.4809/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1252359369 CMS
E.R. Squibb & Sons, L.L.C. $8.6109/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184545081 CMS
LEO Pharma Inc. $3.9909/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1252024037 CMS
PFIZER INC. $9.9909/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1229449399 CMS
Galderma Laboratories, L.P. $12.6609/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234680578 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $34.8309/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1251032402 CMS
Paratek Pharmaceuticals, Inc. $20.5508/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1181756894 CMS
Janssen Biotech, Inc. $10.0408/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175104612 CMS
MAYNE PHARMA COMMERCIAL LLC $11.2008/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1254275511 CMS
ABBVIE INC. $6.3608/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1203126390 CMS
ABBVIE INC. $14.5308/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1203126394 CMS
Galderma Laboratories, L.P. $15.9508/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234680576 CMS
Janssen Biotech, Inc. $22.7108/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175104017 CMS
Janssen Biotech, Inc. $2.8708/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175104380 CMS
Janssen Biotech, Inc. $19.2408/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175104908 CMS
LEO Pharma Inc. $2.9008/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1252024035 CMS
ABBVIE INC. $12.9708/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1203126386 CMS
Arcutis Biotherapeutics, Inc. $7.3608/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1252359359 CMS
Janssen Biotech, Inc. $33.1308/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175104568 CMS
Lilly USA, LLC $6.0808/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186822978 CMS
E.R. Squibb & Sons, L.L.C. $15.5708/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184545065 CMS
MAYNE PHARMA COMMERCIAL LLC $5.3008/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1254275551 CMS
ABBVIE INC. $17.3208/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1203126382 CMS
Incyte Corporation $25.1208/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1226157420 CMS
MAYNE PHARMA COMMERCIAL LLC $5.5508/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1254275569 CMS
PFIZER INC. $17.5308/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1229189770 CMS
E.R. Squibb & Sons, L.L.C. $2.3208/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184545057 CMS
E.R. Squibb & Sons, L.L.C. $9.1108/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184545059 CMS
Janssen Biotech, Inc. $9.6808/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175103934 CMS
Galderma Laboratories, L.P. $18.9308/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234680574 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $15.9708/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1220084910 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $9.3808/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1251032400 CMS
Botanix SB Inc $15.5407/31/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1246263737 CMS
Novartis Pharmaceuticals Corporation $22.0907/31/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200731765 CMS
Janssen Biotech, Inc. $6.6507/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175103865 CMS
ABBVIE INC. $9.4007/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1203126373 CMS
ABBVIE INC. $30.1007/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1203126377 CMS
Arcutis Biotherapeutics, Inc. $12.4007/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1252359361 CMS
Organon LLC $8.7507/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1237658830 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $3,657.09 221
PY2020 $2,051.70 142
PY2021 $2,940.12 187
PY2022 $4,139.03 300
PY2023 $4,241.61 217
PY2024 $3,994.79 248
PY2025 $6,884.73 340

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $314,270.16 22
PY2024 Principal investigator $299,406.57 18
PY2023 Principal investigator $787.36 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

22 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 SANOFI US SERVICES INC. $9,568.00 12/15/2025 Non-covered Recipient Entity
Stride Clinical Research Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226134025
Principal investigator 1 SANOFI US SERVICES INC. $6,300.00 11/24/2025 Non-covered Recipient Entity
Stride Clinical Research Llc
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) No dispute reported 06/30/2026 1226134022
Principal investigator 1 SANOFI US SERVICES INC. $36,558.00 11/10/2025 Non-covered Recipient Entity
Stride Clinical Research Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226134015
Principal investigator 1 SANOFI US SERVICES INC. $10,244.00 10/14/2025 Non-covered Recipient Entity
Stride Clinical Research Llc
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) No dispute reported 06/30/2026 1226134011
Principal investigator 1 SANOFI US SERVICES INC. $13,192.00 09/22/2025 Non-covered Recipient Entity
Stride Clinical Research Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226134006
Principal investigator 1 SANOFI US SERVICES INC. $19,300.00 09/15/2025 Non-covered Recipient Entity
Stride Clinical Research Llc
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) No dispute reported 06/30/2026 1226134002
Principal investigator 1 SANOFI US SERVICES INC. $8,512.00 08/18/2025 Non-covered Recipient Entity
Stride Clinical Research Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226133984
Principal investigator 1 SANOFI US SERVICES INC. $22,513.00 07/14/2025 Non-covered Recipient Entity
Stride Clinical Research Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226133975
Principal investigator 1 SANOFI US SERVICES INC. $4,719.00 07/02/2025 Non-covered Recipient Entity
Stride Clinical Research Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226133980
Principal investigator 1 SANOFI US SERVICES INC. $24,082.00 06/16/2025 Non-covered Recipient Entity
Stride Clinical Research Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226133963
Principal investigator 1 SANOFI US SERVICES INC. $9,934.60 05/19/2025 Non-covered Recipient Entity
Stride Clinical Research Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226133967
Principal investigator 1 SANOFI US SERVICES INC. $23,644.00 05/19/2025 Non-covered Recipient Entity
Stride Clinical Research Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226133971
Principal investigator 1 SANOFI US SERVICES INC. $8,203.40 04/28/2025 Non-covered Recipient Entity
Stride Clinical Research Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226133952
Principal investigator 1 Amgen Inc. $5,096.93 04/23/2025 Non-covered Recipient Entity
STRIDE CLINICAL RESEARCH LLC
A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND) No dispute reported 06/30/2026 1246648786
Principal investigator 1 SANOFI US SERVICES INC. $13,565.00 04/14/2025 Non-covered Recipient Entity
Stride Clinical Research Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226133955
Principal investigator 1 SANOFI US SERVICES INC. $26,441.00 03/24/2025 Non-covered Recipient Entity
Stride Clinical Research Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226133935
Principal investigator 1 SANOFI US SERVICES INC. $5,027.10 02/24/2025 Non-covered Recipient Entity
Stride Clinical Research Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226133930
Principal investigator 1 SANOFI US SERVICES INC. $10,447.00 02/04/2025 Non-covered Recipient Entity
Stride Clinical Research Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226133922
Principal investigator 1 Amgen Inc. $1,129.07 01/27/2025 Non-covered Recipient Entity
STRIDE CLINICAL RESEARCH LLC
A Phase 3, Multi-center, Open-label, Single-arm Study to Assess the Safety of Apremilast (AMG 407) in Pediatric Participants From 6 Through 17 Years of Age With Mild to Moderate Plaque Psoriasis No dispute reported 06/30/2026 1246648790
Principal investigator 1 SANOFI US SERVICES INC. $3,831.00 01/21/2025 Non-covered Recipient Entity
Stride Clinical Research Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226133919
Principal investigator 1 SANOFI US SERVICES INC. $35,300.00 01/21/2025 Non-covered Recipient Entity
Stride Clinical Research Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226133927
Principal investigator 1 Amgen Inc. $16,663.06 01/02/2025 Non-covered Recipient Entity
STRIDE CLINICAL RESEARCH LLC
A Phase 3, Randomized, 52-week, Placebo-controlled, Double-blind Study With Re-randomization to Assess the Efficacy, Safety, and Tolerability of Rocatinlimab (AMG 451) in Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASTRO) No dispute reported 06/30/2026 1246648798